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For several decades, p53 has been detected in cancer biopsies by virtue of its high pro-
tein expression level which is considered indicative of mutation. Surprisingly, however, 
mouse genetic studies revealed that mutant p53 is inherently labile, similar to its wild type 
(wt) counterpart. Consistently, in response to stress conditions, both wt and mutant p53 
accumulate in cells. While wt p53 returns to basal level following recovery from stress, 
mutant p53 remains stable. In part, this can be explained in mutant p53-expressing cells 
by the lack of an auto-regulatory loop with Mdm2 and other negative regulators, which 
are pivotal for wt p53 regulation. Further, additional protective mechanisms are acquired 
by mutant p53, largely mediated by the co-chaperones and their paralogs, the stress-in-
duced heat shock proteins. Consequently, mutant p53 is accumulated in cancer cells 
in response to chronic stress and this accumulation is critical for its oncogenic gain of 
functions (GOF). Building on the extensive knowledge regarding wt p53, the regulation 
of mutant p53 is unraveling. In this review, we describe the current understanding on 
the major levels at which mutant p53 is regulated. These include the regulation of p53 
protein levels by microRNA and by enzymes controlling p53 proteasomal degradation.
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inTRODUCTiOn
Wild type (wt) p53 is a tumor suppressor, which plays a key role in the cellular stress response. 
Abrogating p53 function is a key event in human cancer, leading to deregulated cell cycle, genomic 
instability, resistance to stress signals, and ultimately leading to cancer development (1, 2). 
Dysfunction of p53 occurs in half the cases of cancers by direct mutations in the gene, whereas in 
the remainder, p53 becomes dysfunctional through a variety of regulatory breakdowns. Mutant p53 
fails to emulate the transcriptional program executed by wt p53 to provide a robust response to stress.
Most p53 mutations are missense (hotspot mutations – R175, G245, R248, R249, R273, R282) 
and occur at its DNA-binding domain, which accounts for the improper DNA engagement and 
disruption of transcriptional activity. P53 mutants also gain new oncogenic functions  including 
resistance to chemotherapies, enhanced cell growth, metabolism, and invasion [reviewed in 
Ref. (3, 4)].
Surprisingly, mutant p53, like its wt counterpart, is inherently labile (5–7). Sustained degradation 
of wt p53 in healthy cells protects them against potent cell growth inhibition, while stress provokes 
p53 accumulation and activation (8). Similarly, mutant p53 accumulates in response to stress (7). 
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Thus, both wt and mutant p53 need to accumulate in order to 
execute their respective functions: wt p53 suppresses cancer while 
mutant p53 promotes cancer through its GOFs. It is therefore 
of great clinical importance to understand how wt and mutant 
p53 are regulated if we are to tailor treatments according to p53 
status. That is, either reactivating wt p53 expression and function 
or counteracting mutant p53. In this review, we will outline the 
major levels at which mutant p53 is regulated and discuss the 
major players. As most of the regulation appears to occur post-
transcriptionally [reviewed in Ref. (9)], this will form the major 
focus of this review.
ReGULATiOn OF MUTAnT p53 BY 
microRnA
MicroRNAs (miRNA) are the best-characterized members of 
the non-coding RNAs (ncRNAs) family. Typically these are 
18–24 nucleotide (nt) RNA molecules that are not translated into 
proteins, and target messenger RNA (mRNA) species, through 
engagement of as few as six complementary nucleotides (10). 
Canonically, mature miRNAs bind mRNA 3′-untranslated-
regions (3′-UTRs) and promote either target degradation or 
translational inhibition. Through engagement of coding regions 
(11), 5′-UTR (12), and open reading frames (ORF) (13), miRNAs 
can also regulate translation. The targeting flexibility of miRNAs 
allows them to affect multiple targets that are pertinent to both 
tumor suppression and oncogenesis: gene expression, protein 
regulation, homeostasis, and diseases.
The expression of both wt and mutant p53 are subject to 
miRNA regulation directly. MiRNAs targeting p53 mRNA are 
incapable of discriminating between its wt and mutant mRNAs, 
unless an miRNA directly targets a mutated site. MiR-125b was 
the first miRNA demonstrated to bind p53 3′-UTR mRNA caus-
ing down-regulation of p53 protein and a consequent reduction 
in its activity, in human neuroblastoma cells and primary human 
lung fibroblasts (14). Additional p53-directed miRNAs have 
been identified both experimentally and from in silico analyses 
(Figure 1).
MicroRNAs also regulate p53 protein stability indirectly, by 
targeting its key regulators. For instance, the E3 ubiquitin ligase 
Mdm2, which is the major negative regulator of p53 [reviewed in 
Ref. (8, 15)] is extensively targeted by miRNAs for degradation. As 
a consequence of Mdm2 targeting, p53 (wt or mutant) is released 
from Mdm2-mediated ubiquitination and subsequent protea-
somal degradation (Figure 1). Mdm4 (also known as MdmX), 
which is an Mdm2-related protein, is another key inhibitor of p53 
transcriptional activity (16, 17) and is also targeted by miRNAs 
(Figure 1). Although miRNAs predominantly degrade mRNAs, 
an exceptional instance is miR-885-3p, which engages the 5′-UTR 
of Mdm4 mRNA and elevates Mdm4 protein levels (12).
Apart from Mdm2 and Mdm4, miRNAs also stabilize p53 
through other regulatory pathways (Figure 1). MiR-29 activates 
p53 by targeting p85-alpha and CDC42 (18), miR-449 targets 
SIRT1 and HDAC1 (19), and miR-32 targets TSC1 and activates 
mTOR in human glioblastoma multiforme (20), all of which lead to 
the stabilization of p53. Recent study by Wang et al. demonstrated 
that miR 542-3p directly targets RPS23, resulting in subsequent 
RPL11 up-regulation, inhibiting Mdm2 and ultimately reducing 
proteasomal degradation of p53 (21).
Significantly for cancer, interaction of miRNAs with wt and 
mutant p53 is not unidirectional, and expression levels and 
biogenesis of miRNAs are affected by p53. Suzuki et al. demon-
strated that wt p53 enhances post-transcriptional maturation of 
miR-16-1, miR-143, and miR-145 in response to DNA damage, 
while mutant p53 attenuates miRNA processing (22). Muller 
et al. further demonstrated that mutant p53 modulates miRNA 
 processing, through direct inhibition of TAp63-mediated 
transcriptional activation of Dicer, and also through a TAp63-
independent manner (23). Apart from global modulation 
of miRNA biogenesis, mutant p53 also affects expression of 
miRNAs, principally by downregulating tumor-suppressive 
miRNAs  –  miR-130b in endometrial cancer (24), miR-27a in 
breast cancer cells (MDA-MB-468) (25), miR-223 in breast and 
colon cells (26), let-7i in breast cancer and DLD1 cells (colorectal 
cancer) (27), and miR-205 (28), and elevating oncogenic miR-
NAs: miR-128-2 (29) and miR-155 in breast cancer cells (30) to 
mediate its oncogenic functions.
These studies collectively suggest that intertwined regulation 
of miRNAs, wt, and mutant p53 is vital to cancer. Given the 
importance of ncRNA in the regulation of wt and mutant p53, 
ncRNA represents feasible therapeutic targets for the develop-
ment of new approach targeting mutant p53 in cancer.
ReGULATiOn OF MUTAnT p53 PROTein 
STABiLiTY
Overall, wt p53 is predominantly regulated at the protein stability 
level, under normal and stress conditions. Extensive study has 
defined that p53 stability is dictated by a variety of stabilizing 
post-translational modifications (PTM), while its degradation is 
largely the consequence of ubiquitination, executed by several E3 
ligases [reviewed in Ref. (31, 32)]. Despite a drastic difference 
between the stability of mutant versus wt p53 in cancer cells, the 
majority of the regulatory pathways of p53 are shared between wt 
and mutant p53. However, a number of key differences promote 
the chronic stabilization and activation of mutant p53, which 
drive its oncogenic GOF. Understanding the regulation of mutant 
p53 has direct clinical implications. In this section, we will cover 
the major levels of mutant p53 regulation, with a focus on the 
degradation of mutant p53.
ReGULATiOn OF MUTAnT p53 
DeGRADATiOn
p53 stability is tightly controlled by ubiquitin E3 ligases, which 
together with the enzymatic activities of E1 and E2, and in certain 
cases also E4 ligases coordinate the efficient degradation of pro-
teins through the 26S proteasome machinery (33). The temporal 
and spatial modulation of the degradation of p53 is achieved by 
PTMs described below. In this section, we will outline the major 
E3 ligases that have been shown to control mutant p53 stability. 
A paradigm shift in our understanding of mutant p53 stability 
FiGURe 1 | MicroRnAs targeting p53: miR-125b, miR-504, miR-1285, miR-92, miR-141, miR-380-5p, miR-15a, miR-16, miR-25, miR-30d, miR-200a 
[reviewed in Ref. (88)], miR-453 (89), miR-98 (89), miR-19b (90), miR-518c (91), and miR-638 (91). MicroRNAs targeting MDM2: miR-192, miR-194, miR-215, 
miR-221, miR-605, miR-17-3p, miR-193a, miR-25, miR-32, miR-143, miR-145, miR-18b, miR-661 [reviewed in Ref. (15)], miR-339-5p (92, 93), miR-660 (94), and 
miR-509-5p (95). MicroRNAs targeting MDM4: miR-191, miR-10a, miR-885-3p, miR-34a, miR-661 [reviewed in Ref. (15)], miR-887 (96), and let-7 (11).
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was demonstrated in the studies of mutant p53 knock-in mice 
(5, 34). These papers showed for the first time that mutant p53 is 
inherently labile in vivo.
In the case of wt p53, the key physiological E3 ligase is Mdm2, 
which maintains p53 at low levels under basal conditions, and 
during recovery from stress (35, 36). Similarly, Mdm2 maintains 
the low basal levels of mutant p53 in vivo (7). In contrast to wt 
p53, mutant p53 does not form a feedback loop with Mdm2, as 
it is incapable of inducing Mdm2 transcription (37). Therefore, 
following stress-induced stabilization of wt and mutant p53, only 
wt p53 recovers to basal levels under the influence of Mdm2 
(Figure  2). This can be corrected by enforced expression of 
Mdm2, which is able to efficiently degrade of mutant p53 (35). 
Mdm2 interacts with multiple domains of p53, which allows it 
to bind even to conformational p53 mutants, which are mis-
sense p53 mutations that either locally or globally disrupt the 
structure of p53, as distinct from “DNA contact mutants” (38, 
39). The overall efficiency of mutant p53 ubiquitination, however, 
is reduced compared with that of wt p53 (40). The ubiquitina-
tion of mutant p53 is also enhanced by the activity of other E3 
ligases: CHIP and Cop1 (40). Although ubiquitination of p53 by 
Mdm2 is enhanced by ubiquitin-interacting protein, hHR23a, the 
consequent ubiquitinated p53 accumulates but is not degraded 
(41). In a series of key in vivo studies, Terzian et al. (7) and Suh 
et al. (20) demonstrated that stress conditions (including oxida-
tive stress, DNA damage) and oncogenic stress (such as the loss 
of p16) promote stabilization of mutant p53 and contribute to 
tumorigenesis. Subsequent studies have shown that multiple 
oncogenic effects can stabilize mutant p53 in vivo and drive its 
oncogenic functions. Interestingly, at least in the case of PML loss, 
the impact on mutant p53 GOF is gender-specific (42).
Degradation of mutant p53 has also been described to occur 
via alternative forms of autophagy. The first is: “Macroautophagy,” 
which is triggered in response to starvation to recycle cellular 
contents through the lysosomes. A specific form of starvation is 
glucose restriction, which increases mutant p53 deacetylation, 
and sends it to degrade through the autophagic machinery. 
This degradation is Mdm2-dependent (43), but does not 
involve the proteasome (43, 44). A second form is: selective 
“chaperone-mediated autophagy” (CMA), in which specific 
cytosolic proteins are engaged by heat shock proteins (HSPs) 
and targeted to lysosomes. CMA is a normal cellular process 
that becomes more active in response to nutrient deprivation 
(43–46). Although mechanisms like autophagy seem to be less 
FiGURe 2 | Regulation of wt and mutant p53 stability in response to stress. Wt and mutant p53 are maintained at basal levels by Mdm2-mediated 
degradation. Upon stress stimulus, events such as post-translational modifications (PTM) result in stabilization and accumulation of p53. During recovery from 
stress, wt p53 returns to basal levels as a result of negative feedback through Mdm2. However, mutant p53 accumulates due to its failure to transactivate Mdm2. 
Mutant p53 is also protected from Mdm2 and CHIP mediated ubiquitination by chaperone proteins. This can be overcome by treatment with Hsp90 inhibitors. 
Treatment of cells with As2O3 induces the E3 ligase Pirh2, which ubiquitinates mutant p53.
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specific than proteasomal degradation, it has been observed 
that ubiquitinated proteins are targeted for lysosomal degrada-
tion and could play a major role in regulating mutant p53 (47).
CHIP is a chaperone-dependent E3 ligase able to ubiquitinate 
misfolded proteins, a process which is assisted by the Hsp70/90 
chaperone machinery. Hsp90-bound substrates are protected 
from ubiquitination, whereas Hsp70-bound substrates are 
ubiquitinated by CHIP (48). Interestingly, Hsp70 is found to 
partially inhibit Mdm2-mediated degradation of mutant p53. 
This apparent discrepancy in Hsp70 activity with respect to the 
two E3 ligases is not completely understood. In contrast, Hsp90 
protects mutant p53 from both CHIP and Mdm2-mediated 
degradation (49, 50). This is because mutant p53, unlike wt p53, 
forms a stable complex with Hsp90 (51, 52). Inhibition of Hsp90 
by 17AAG or siRNA against HSF1 (a major transcription factor 
for Hsp) enhances the ubiquitination and degradation of mutant 
p53 (Figure 2) (53, 54). Indeed, it was observed that inhibition 
of Hsp90 reduced the viability of mutant p53-expressing cancer 
cells of breast (MBA-MB-468, MDA-MB-231, T47D), prostate 
(DU145), and colon (SW480) (49). Similarly, inhibition of 
HDAC6, a positive regulator of Hsp90, destabilizes mutant p53 
and is preferentially toxic to mutant p53-expressing cancer cell 
lines (54, 55). Hsp90 directly, or indirectly via its transcriptional 
activator HSF1, is upregulated in many cancer types, which may 
contribute to mutant p53 stabilization (56). Mutant p53 exists in 
a positive forward loop with HSF1. Mutant p53 enhances HSF1 
recruitment to DNA, thereby increasing the levels of HSPs, 
which further stabilize mutant p53 (57, 58). Indeed, treatment 
with Hsp90 inhibitor, 17DMAG (a derivative of 17AAG), can 
greatly reduce lymphoma formation and is known to improve 
survival in mice with mutant p53 (59). Lastly, RING domain 
containing E3 ligase, Pirh2, which directly ubiquitinates wt 
p53 (60), also interacts with and promotes the ubiquitination 
of mutant p53 (61, 62). Since Pirh2 is a p53 target gene, this 
negative feedback regulatory loop is interrupted by mutations in 
p53 (60). Treatment of mutant p53-expressing cells with Arsenic 
trioxide can induce Pirh2-mediated proteasomal degradation of 
mutant p53 (Figure 2) (62). The role of other E3 ligases, includ-
ing ARF-BP1, which regulate wt p53, have been shown not to 
regulate mutant p53 [(40) and reviewed in Ref. (8)].
Countering the E3 ligases are the deubiquitinating enzymes 
(DUBs), which cleave ubiquitin from proteins. Unlike E3 
ligases, the role of DUBs in controlling mutant p53 stability 
is poorly explored. USP10 deubiquitinates and stabilizes both 
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wt and mutant p53 (63). Inhibition of USP10 by the protein 
spautin-1 reduces mutant p53 levels under glucose-restricted 
conditions (46). The USP7 DUB has a complex interplay with 
both wt p53 and Mdm2, and it deubiquitinates the p53 activator, 
Tip60 (64). To date, no correlation between USP7 and p53 status 
has been identified in cancers (65, 66). In wt p53-expressing cell 
lines, inhibition of USP7 stabilizes p53 and promotes apoptosis. 
But in at least one mutant p53-expressing cell line, the inhibitor 
had no effect (67). ABRO1 is able to deubiquitinate wt p53 and 
stabilize it by facilitating its interaction with USP7. However, 
there is no information pertaining to its ability to deubiquit-
inate mutant p53. Overexpression of ABRO1 in HT29 (colo-
rectal adenocarcinoma) and BT474 (breast cancer) cells (both 
expressing mutant p53) results in increased cell growth, which 
can be correlated with mutant p53 stability (68). Another DUB, 
UCHL1, stabilizes wt and mutant p53 levels in breast cancer cell 
lines and affects cell viability by a mechanism remaining to be 
explored (69). USP29 can also deubiquitinate p53 in response 
to oxidative stress (70).
Although much of the focus in the field has been devoted to 
the 26S-mediated proteasomal degradation of p53 during post-
stress recovery, the 20S proteasome has been identified as the 
destination of unmodified p53 that is inherently unstable, unless 
protected by the NADH quinone oxidoreductase 1 (NQO1). 
Specifically, inhibition of NQO1 (for example by dicoumarol) 
promotes p53 degradation through the 20S proteasome in an 
Mdm2-independent manner. Interestingly, mutant p53 interacts 
strongly with NQO1, rendering it resistant to NQO1 inhibitors 
[reviewed in Ref. (71)]. Pertinently, NQO1 is elevated in many 
cancers, which may contribute to stabilization of mutant p53 in 
these cases [reviewed in Ref. (72)].
Free ribosomal proteins are known to regulate the Mdm2/
MdmX-p53 axis and activate wt p53, thereby inhibiting tumor 
proliferation [reviewed in Ref. (73)]. For example, RPS27 is 
repressed by wt but not mutant p53, and increased expression 
of RPS27 stabilizes mutant p53 protein, thereby forming a feed 
forward loop in cancer (74). On the other hand, RPL26 not only 
binds to the 5′-UTR of p53 mRNA and enhances translation 
but also interacts with Mdm2 and protects p53 from degrada-
tion (75, 76).
POST-TRAnSLATiOnAL MODiFiCATiOnS 
OF MUTAnT p53
The regulation of wt p53 degradation is modulated by PTMs. Wt 
p53 is extensively modified post-translationally in response to 
stress conditions, which lead to the stabilization and/or activation 
of p53 [reviewed in Ref. (31)]. Critically, in most of the tested 
cases, the PTMs of p53 are non-discriminatory between wt and 
mutant proteins (7, 31, 77). Some of these modifications contrib-
ute to mutant p53 stability by shielding it from degradation by 
Mdm2 (Figure 2). Specifically, phosphorylation of p53 on serine 
20 and threonine 18 in response to DNA damage protects it from 
Mdm2 and leads to its activation and stabilization (77–79). These 
phosphorylations are also induced on mutant p53 in response to 
stress (49, 77). Mutant p53 also escapes from Mdm2 by constitu-
tive phosphorylation by ERK (80). Similarly, activation of SIRT1, 
which deacetylates mutant p53, can reduce mutant p53 levels 
in triple-negative breast cancer cell lines, revealing the role of 
acetylation in stability of the mutant protein (81, 82).
In addition to mutant p53 itself, modifications of Mdm2/
MdmX contribute to the protection of mutant p53 from these key 
inhibitors. In response to DNA damage, Mdm2 is phosphorylated 
by ATM and c-Abl, which compromises the ability of Mdm2 to 
degrade p53 (83, 84). ATM-mediated phosphorylation contrib-
utes also through the impaired oligomerization of Mdm2 (85). 
Similarly, MdmX, the key inhibitor of p53 is phosphorylated by 
ATM and c-Abl, which impairs its capacity to inhibit p53 (86, 87). 
To what extent these key phosphorylations affect mutant p53 is 
yet to be demonstrated. The indiscriminate modifications of wt 
versus mutant p53 in response to stress can contribute to mutant 
p53 accumulation and activation.
COnCLUDinG ReMARKS
While wt and mutant p53 have distinct and opposing effects on 
cancer cells, many aspects of their regulation are shared. The 
majority of the positive and negative regulators of wt p53 that 
have been tested have a similar regulatory effect on mutant p53. 
Critically, however, the tightly controlled myriad of positive and 
negative auto-regulatory loops, which govern wt p53 levels, is 
uncoupled in the context of mutant p53. In addition, mutant p53 
is recognized as a misfolded protein by the heat shock protein 
chaperons. Together, these contribute to the protection of mutant 
p53 from the well-coordinated recovery from stress conditions. 
This results in the chronic accumulation of active mutant p53, 
which exerts its gain of functions. It is therefore of prime impor-
tance to screen patients for p53 mutations prior to treatments, 
which are known to activate and stabilize p53. The identification 
of mechanisms that protect mutant p53, as shown by the chap-
eron HSP proteins, identifies novel approaches to expose mutant 
p53 to its negative regulators and drive its destruction. Future 
studies identifying the unique protectors of mutant p53 are a 
rational approach to define novel approaches to target mutant 
p53 in cancer cells.
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